|Day Low/High||41.75 / 42.08|
|52 Wk Low/High||37.43 / 50.65|
- Company invests €66 million in Chengdu, Sichuan province, China
- Toujeo (insulin glargine injection 300 Units/mL) met primary endpoint in lowering blood sugar levels and was non-inferior to insulin degludec in adults with type 2 diabetes not previously on insulin
Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.
Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Three-quarters of employers are worried about the impact of unmanaged chronic disease Two-thirds (66%) of Canadian employees would consent to receive personalized information based on their own benefits claims...
While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.
Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.
The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.
- If approved, health care professionals will be able to use the same 0.5 mL dose of Fluzone Quadrivalent vaccine with all patients ages 6 months and older for whom flu vaccination is recommended - which may provide more flexibility and convenience to immunizers.
The Philippine government says Sanofi knew that the vaccine should not have been given to people who have never had dengue fever.
The charges were related to an interest-rate problem.
Study is the First "Prevention of Infection" Trial Conducted for Tuberculosis, the World's Leading Infectious Disease Killer
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: OMC, WMS Downgrades: ALSK, ATV, BP, CARB, CMP, CRL, DAN, FRT, SNY, VNO, WU, ZIXI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.
A steeper fall might cause both buyers and sellers to re-think potential deals, but so far that doesn't seem to be the case yet.
What is the strike price, and/or what the expiration date might be on such plunge protection?
A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.
U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.
As the Trump administration reportedly considers government controlled 5G, investors prepare for a hectic week of earnings.
Consumer spending should be more than solid given wage increases.
Here's what you need to know now for Monday, Jan. 22.
With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.
A flurry of high-priced merger-and-acquisition activity explains the move in Allergan.
Stocks hit fresh records on Monday after a deal is reached to end the three-day government shutdown.
Stocks turn higher on Monday, as investors watch for the impact of a federal government shutdown that entered its third day.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.